IRCT20240723062520N1招募中3 期
Formulation and clinical assessment of erythropoietin oral gel in treatment of stomatitis caused by chemotherapy: A double blind clinical trial
Shahre-kord University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 14 years 至 60 years(—)
- 性别
- All
入选标准
- •Patients who receive chemotherapy for solid tumor or hematology and the treatment regimen is capable of causing mucositis.
- •Having neutrophils between 1800 and 7700 per cubic millimeter
- •Being 14 to 60 years old
排除标准
- •Having an underlying disease of diabetes, kidney disease, liver disease, digestive diseases, allergy, allergic rhinitis, asthma, having an immune system deficiency disease
- •History of smoking, hookah, tobacco, drugs and alcohol, receiving radiation therapy for one hour
- •Death or non-cooperation of patients
研究者
相似试验
招募中
不适用
Erythropoietin therapy for children with cerebral palsyDiseases of the nervous systemKCT0000482Bundang CHA General Hospital10
已完成
3 期
The efficacy of erythropoietin in the treatment of anemia in patients hospitalized in Intensive Care Unit(ICU)Anaemia.Anaemia, unspecifiedIRCT2014071718517N1Vice Chancellor for research of Ardabil University of Medical Sciences70
尚未招募
Unknown
To assess the effect of erythropoietin (EPO)in augmentation of peri implant tissues.CTRI/2023/08/056074one
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148
暂停
1 期
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I.Acute Cerebral Ischemic Stroke.RPCEC00000078Center of Molecular Inmunology(CIM)20
